Transfer of metformin across the rat placenta is mediated by organic cation transporter 3 (OCT3/SLC22A3) and multidrug and toxin extrusion 1 (MATE1/SLC47A1) protein

Reproductive Toxicology

Volumn 39, Issue , 2013, Pages 17-22

  Ahmadimoghaddam, Davoud ^a   Staud, Frantisek ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Gestational diabetes mellitus; Metformin; Multidrug and toxin extrusion 1; Organic cation transporter 3; Pharmacokinetics; Placenta; Pregnancy

Indexed keywords

CARRIER PROTEIN; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION 1 PROTEIN; ORGANIC CATION TRANSPORTER 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG TRANSPORT; FEMALE; FETUS; FETUS CIRCULATION; MOTHER FETUS RELATIONSHIP; NONHUMAN; PH MEASUREMENT; PLACENTA PERFUSION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RAT;

ANIMALS; ANTIPORTERS; FEMALE; HYPOGLYCEMIC AGENTS; MATERNAL-FETAL EXCHANGE; METFORMIN; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; ORGANIC CATION TRANSPORT PROTEINS; PLACENTA; PREGNANCY; RATS; RATS, WISTAR;

RATTUS;

EID: 84876709243     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2013.03.001     Document Type: Article

References (44)

1. Gauster M., Desoye G., Totsch M., Hiden U. The placenta and gestational diabetes mellitus. Current Diabetes Reports 2012, 12:16-23.
2. Ben-Haroush A., Yogev Y., Hod M. Epidemiology of gestational diabetes mellitus and its association with type 2 diabetes. Diabetic Medicine 2004, 21:103-113.
3. Gedeon C., Koren G. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta 2006, 27:861-868.
4. Renda E., Faraci M., Di Prima F.A., Valenti O., Hyseni E., Monte S., et al. Treatment of gestational diabetes: oral hypoglycemic agents or insulin. Journal of Prenatal Medicine 2011, 5:63-64.
5. Rowan J.A., Hague W.M., Gao W., Battin M.R., Moore M.P. Metformin versus insulin for the treatment of gestational diabetes. The New England Journal of Medicine 2008, 358:2003-2015.
6. Waugh N., Royle P., Clar C., Henderson R., Cummins E., Hadden D., et al. Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee. Health Technology Assessment 2010, 14:1-183.
7. Nicholson W., Bolen S., Witkop C.T., Neale D., Wilson L., Bass E. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. Obstetrics and Gynecology 2009, 113:193-205.
8. Ghazeeri G.S., Nassar A.H., Younes Z., Awwad J.T. Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. Acta Obstetricia et Gynecologica Scandinavica 2012, 91:658-678.
9. Kumar P., Khan K. Effects of metformin use in pregnant patients with polycystic ovary syndrome. Journal of Human Reproductive Sciences 2012, 5:166-169.
10. Morin-Papunen L., Rantala A.S., Unkila-Kallio L., Tiitinen A., Hippelainen M., Perheentupa A., et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. Journal of Clinical Endocrinology and Metabolism 2012, 97:1492-1500.
11. Cicero A.F., Tartagni E., Ertek S. Metformin and its clinical use: new insights for an old drug in clinical practice. Archives of Medical Science 2012, 8:907-917.
12. Goh J.E., Sadler L., Rowan J. Metformin for gestational diabetes in routine clinical practice. Diabetic Medicine 2011, 28:1082-1087.
13. Rowan J.A., Rush E.C., Obolonkin V., Battin M., Wouldes T., Hague W.M. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. Diabetes Care 2011, 34:2279-2284.
14. Kovo M., Haroutiunian S., Feldman N., Hoffman A., Glezerman M. Determination of metformin transfer across the human placenta using a dually perfused ex vivo placental cotyledon model. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2008, 136:29-33.
15. Kovo M., Kogman N., Ovadia O., Nakash I., Golan A., Hoffman A. Carrier-mediated transport of metformin across the human placenta determined by using the ex vivo perfusion of the placental cotyledon model. Prenatal Diagnosis 2008, 28:544-548.
16. Nanovskaya T.N., Nekhayeva I.A., Patrikeeva S.L., Hankins G.D., Ahmed M.S. Transfer of metformin across the dually perfused human placental lobule. American Journal of Obstetrics and Gynecology 2006, 195:1081-1085.
17. Tertti K., Ekblad U., Heikkinen T., Rahi M., Ronnemaa T., Laine K. The role of organic cation transporters (OCTs) in the transfer of metformin in the dually perfused human placenta. European Journal of Pharmaceutical Sciences 2010, 39:76-81.
18. Staud F., Cerveny L., Ceckova M. Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. Journal of Drug Targeting 2012, 20:736-763.
19. Kimura N., Masuda S., Katsura T., Inui K. Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. Biochemical Pharmacology 2009, 77:1429-1436.
20. Kimura N., Okuda M., Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharmacological Research 2005, 22:255-259.
21. Graham G.G., Punt J., Arora M., Day R.O., Doogue M.P., Duong J.K., et al. Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics 2011, 50:81-98.
22. Tsuda M., Terada T., Mizuno T., Katsura T., Shimakura J., Inui K. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Molecular Pharmacology 2009, 75:1280-1286.
23. Tsuda M., Terada T., Ueba M., Sato T., Masuda S., Katsura T., et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. Journal of Pharmacology and Experimental Therapeutics 2009, 329:185-191.
24. Terada T., Inui K. Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). Biochemical Pharmacology 2008, 75:1689-1696.
25. Ahmadimoghaddam D., Hofman J., Zemankova L., Nachtigal P., Dolezelova E., Cerveny L., et al. Synchronized activity of organic cation transporter 3 (OCT3/SLC22A3) and multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter in transplacental passage of MPP+ in rat. Toxicological Sciences 2012, 128:471-481.
26. Konig J., Zolk O., Singer K., Hoffmann C., Fromm M.F. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. British Journal of Pharmacology 2010, 163:546-555.
27. Nies A.T., Koepsell H., Damme K., Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handbook of Experimental Pharmacology 2011, 10:5-67.
28. Cygalova L.H., Hofman J., Ceckova M., Staud F. Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility. Journal of Pharmacology and Experimental Therapeutics 2009, 331:1118-1125.
29. Pavek P., Fendrich Z., Staud F., Malakova J., Brozmanova H., Laznicek M., et al. Influence of P-glycoprotein on the transplacental passage of cyclosporine. Journal of Pharmaceutical Sciences 2001, 90:1583-1592.
30. Staud F., Vackova Z., Pospechova K., Pavek P., Ceckova M., Libra A., et al. Expression and transport activity of breast cancer resistance protein (Bcrp/Abcg2) in dually perfused rat placenta and HRP-1 cell line. Journal of Pharmacology and Experimental Therapeutics 2006, 319:53-62.
31. Ahmadimoghaddam D., Zemankova L., Nachtigal P., Dolezelova E., Neumanova Z., Cerveny L., et al. Organic cation transporter 3 (OCT3/SLC22A3) and multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter in the placenta and fetal tissues: expression profile and fetus protective role at different stages of gestation. Biology of Reproduction 2013, 10.1095/biolreprod.112.105064.
32. Kertschanska S., Stulcova B., Kaufmann P., Stulc J. Distensible transtrophoblastic channels in the rat placenta. Placenta 2000, 21:670-677.
33. Stulc J., Stulcova B., Sibley C.P. Mechanisms of the fetomaternal transfer of Na+ across the dually perfused placenta of the rat. Placenta 1995, 16:127-135.
34. Staud F., Mazancova K., Miksik I., Pavek P., Fendrich Z., Pacha J. Corticosterone transfer and metabolism in the dually perfused rat placenta: effect of 11beta-hydroxysteroid dehydrogenase type 2. Placenta 2006, 27:171-180.
35. Jakoubek V., Bibova J., Herget J., Hampl V. Chronic hypoxia increases fetoplacental vascular resistance and vasoconstrictor reactivity in the rat. American Journal of Physiology: Heart and Circulatory Physiology 2008, 294:H1638-H1644.
36. Vackova Z., Vagnerova K., Libra A., Miksik I., Pacha J., Staud F. Dexamethasone and betamethasone administration during pregnancy affects expression and function of 11 beta-hydroxysteroid dehydrogenase type 2 in the rat placenta. Reproductive Toxicology 2009, 28:46-51.
37. Klaassen C.D., Aleksunes L.M. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacological Reviews 2010, 62:1-96.
38. Tsuda M., Terada T., Asaka J., Ueba M., Katsura T., Inui K. Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1. American Journal of Physiology Renal Physiology 2007, 292:F593-F598.
39. Lickteig A.J., Cheng X., Augustine L.M., Klaassen C.D., Cherrington N.J. Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. Life Sciences 2008, 83:59-64.
40. Aleksunes L.M., Cui Y., Klaassen C.D. Prominent expression of xenobiotic efflux transporters in mouse extraembryonic fetal membranes compared with placenta. Drug Metabolism and Disposition 2008, 36:1960-1970.
41. Otsuka M., Matsumoto T., Morimoto R., Arioka S., Omote H., Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:17923-17928.
42. Ito S., Kusuhara H., Kuroiwa Y., Wu C., Moriyama Y., Inoue K., et al. Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. Journal of Pharmacology and Experimental Therapeutics 2010, 333:341-350.
43. Becker M.L., Visser L.E., van Schaik R.H., Hofman A., Uitterlinden A.G., Stricker B.H. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009, 58:745-749.
44. Becker M.L., Visser L.E., van Schaik R.H., Hofman A., Uitterlinden A.G., Stricker B.H. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenetics and Genomics 2010, 20:38-44.